Valid until Jun. 30, 2025 Primary Responsibilities: 1. Responsible for the overall planning of clinical research, including the investigation of clinical trial progress and relevant information of similar varieties at home and abroad, clinical evaluation and feasibility analysis, and the formulation of clinical development strat
-
On August 22, 2024, Cascade Pharmaceuticals announced the official launch of a Phase I clinical trial for its THR-β agonist, CS060380.The trial, titled "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of Single and Multiple Ascending Doses of CS060380 in Healthy Subjects and Participants with Elevated LDL-C", successfully held its kickoff meeting at Xuhui Central Hospital in Shanghai.
-
Recently, Cascade Pharmaceuticals announced that its independently developed Class I new drug, CS060304, has received implicit approval for clinical trial application (IND) from the U.S. Food and Drug Administration (FDA).About CS060304CS060304 is a small molecule agonist targeting thyroid receptor